This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

This study has been completed.
InfoMedics, Inc.
Information provided by (Responsible Party):
Pamlab, Inc. Identifier:
First received: May 20, 2011
Last updated: May 7, 2013
Last verified: May 2013
This study will be an observational study in which patients who have been prescribed CerefolinNAC® are invited to participate in surveys regarding their experiences with CerefolinNAC®. CerefolinNAC® is a medical food indicated for the distinct nutritional requirements of individuals under treatment for early memory loss with particular emphasis for those individuals diagnosed with or at risk for neurovascular oxidative stress and/or hyperhomocysteinemia; mild to moderate cognitive impairment with or without vitamin B12 deficiency, vascular dementia or Alzheimer's disease. The purpose of this study is to increase the understanding of the role of CerefolinNAC® in managing proper neuronal function in the brain, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for early memory loss.

Condition Intervention
Early Memory Loss Mild Cognitive Impairment Alzheimer's Disease Vascular Dementia Other: CerefolinNAC®

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

Resource links provided by NLM:

Further study details as provided by Pamlab, Inc.:

Primary Outcome Measures:
  • To determine if CerefolinNAC® affects a subject's quality of life as measured by the Quality of Life-Alzheimer's Disease Scale (QOL-AD) [ Time Frame: Baseline, Week 6 and Week 12 ]
    The QOL-AD is a brief, 13-item measure designed specifically to obtain a rating of the patient's Quality of Life.

Secondary Outcome Measures:
  • To determine overall patient satisfaction with CerefolinNAC® using a 9-point satisfaction scale [ Time Frame: Weeks 6 and 12 ]

Enrollment: 204
Study Start Date: May 2011
Study Completion Date: December 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Subjects diagnosed with Early Memory Loss who have been prescribed CerefolinNAC® daily.
Other: CerefolinNAC®
CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.

Detailed Description:
Surveys used to conduct this study will be administered via telephone by InfoMedics, Inc., a company with an established system for developing such patient-physician feedback programs. Participating physicians will ask their patients to participate in the program after CerefolinNAC® has been prescribed and provide them with a brochure containing an introduction to the program and instructions on how to enroll. Patients self-enroll, take a brief survey before starting their CerefolinNAC® prescription, and then two brief follow-up surveys at 6 weeks and 12 weeks. As patients complete surveys within the study, their physician will receive individualized feedback reports outlining their patient's treatment experience and progress. Patients will also receive a copy of their own reports, to help encourage them to continue taking CerefolinNAC® as directed. Patients will also receive educational materials about managing their early memory loss.

Ages Eligible for Study:   50 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with Early Memory Loss Who Have Been Prescribed CerefolinNAC®

Inclusion Criteria:

  • New CerefolinNAC® Start
  • Only for patients who have been prescribed CerefolinNAC® to help metabolic management of early memory loss.

Exclusion Criteria:

  • If a participant indicates that he or she did not get a prescription for CerefolinNAC®, he/she will not be able to complete the survey(s).
  • For follow-up surveys, if the participant indicates that he/she has not been taking CerefolinNAC®, he/she will not be able to complete the survey (s).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01370954

United States, North Carolina
Falls Neurology and Memory Center
Hickory, North Carolina, United States, 28601
Sponsors and Collaborators
Pamlab, Inc.
InfoMedics, Inc.
Principal Investigator: Donald E Schmechel, M.D. Falls Neurology and Memory Center
  More Information

Responsible Party: Pamlab, Inc. Identifier: NCT01370954     History of Changes
Other Study ID Numbers: NAC-003
Study First Received: May 20, 2011
Last Updated: May 7, 2013

Keywords provided by Pamlab, Inc.:
early memory loss
pre-alzheimer's disease
cognitive function
folic acid
vitamin B12
oxidative stress
memory deficit

Additional relevant MeSH terms:
Alzheimer Disease
Cognition Disorders
Mild Cognitive Impairment
Dementia, Vascular
Memory Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cerebrovascular Disorders
Intracranial Arteriosclerosis
Intracranial Arterial Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms
Antiviral Agents
Anti-Infective Agents
Respiratory System Agents processed this record on September 19, 2017